免疫组库测序技术在细胞质量控制中的最新进展
段晓宇

湖南工业大学生命科学与化学学院，湖南省株洲市，412007；

摘要：细胞治疗作为一种革命性的医学技术，已在血液肿瘤、自身免疫疾病、慢性感染等领域展现出巨大的临床应用潜力。然而，细胞治疗产品的质量控制仍面临诸多挑战，如细胞表型稳定性、功能一致性、免疫原性评估等。近年来，免疫组库测序（Immune Repertoire Sequencing，IRS）作为一种高通量、精确的分子测序技术，在细胞质量控制（Cell Quality Control，CQC）中发挥着越来越重要的作用。本文综述了免疫组库测序技术的基本原理、关键技术、在细胞治疗质量控制中的应用进展，并探讨其在优化细胞治疗安全性、疗效预测、个性化治疗设计等方面的前景与挑战。

关键词：免疫组库测序技术；细胞治疗；质量控制

参考文献

[1]Raffin C, Vo L T, Bluestone J A. Treg cell-based therapies: challenges and perspectives[J]. Nature Reviews Immunology, 2020, 20(3): 158-172.

[2]Bauernfeind S, Salzberger B, Hitzenbichler F, et al. Association between reactogenicity and immunogenicity after vaccination with BNT162b2[J]. Vaccines, 2021, 9(10): 1089.

[3]Mullard A. FDA approves first BCMA-targeted CAR-T cell therapy[J]. Nature reviews Drug discovery, 2021, 20(5): 332-333.

[4]Mohanty R, Chowdhury C R, Arega S, et al. CAR T cell therapy: A new era for cancer treatment[J]. Oncology reports, 2019, 42(6): 2183-2195.

[5]Bald T, Krummel M F, Smyth M J, et al. The NK cell–cancer cycle: advances and new challenges in NK cell–based immunotherapies[J]. Nature immunology, 2020, 21(8): 835-847.

[6]Rao M, Mason C, Solomon S. Cell therapy worldwide: an incipient revolution[J]. Regenerative Medicine, 2015, 10(2): 181-191.

[7]Shimabukuro-Vornhagen A, Gödel P, Subklewe M, et al. Cytokine release syndrome[J]. Journal for immunotherapy of cancer, 2018, 6: 1-14.

[8]Frey N. Cytokine release syndrome: who is at risk and how to treat[J]. Best Practice & Research Clinical Haematology, 2017, 30(4): 336-340.

[9]Iwasaki A, Medzhitov R. Control of adaptive immunity by the innate immune system[J]. Nature immunology, 2015, 16(4): 343-353.

[10]Song L, Cohen D, Ouyang Z, et al. TRUST4: immune repertoire reconstruction from bulk and single-cell RNA-seq data[J]. Nature methods, 2021, 18(6): 627-630.

[11]Liu H, Pan W, Tang C, et al. The methods and advances of adaptive immune receptors repertoire sequencing[J]. Theranostics, 2021, 11(18): 8945.

[12]Sukumaran A, Ball B, Krieger J R, et al. Cross-kingdom infection of macrophages reveals pathogen-and immune-specific global reprogramming and adaptation[J]. MBio, 2022, 13(4): e01687-22.

[13]Dutta R, Nambirajan A, Mittal S, et al. Cytomorphology of primary pulmonary NUT carcinoma in different cytology preparations[J]. Cancer Cytopathology, 2021, 129(1): 53-61.

[14]Johnson S, Nguyen V, Coder D. Assessment of cell viability[J]. Current protocols in cytometry, 2013, 64(1): 9.2. 1-9.2. 26.

[15]McKinnon K M. Flow cytometry: an overview[J]. Current protocols in immunology, 2018, 120(1): 5.1. 1-5.1. 11.

[16]Cobo F, Cortés J L, Cabrera C, et al. Microbiological contamination in stem cell cultures[J]. Cell Biology International, 2007, 31(9): 991-995.

[17]Brummel K, Eerkens A L, de Bruyn M, et al. Tumour-infiltrating lymphocytes: from prognosis to treatment selection[J]. British Journal of Cancer, 2023, 128(3): 451-458.

[18]Jung S M, Kim W U. Targeted immunotherapy for autoimmune disease[J]. Immune network, 2022, 22(1): e9.

[19]胡静涵, 胡懿凡, 蒋俊锋, 等. 单细胞转录组测序技术及其在肿瘤研究中的应用进展[J]. 海军军医大学学报, 2023, 44(7): 800-807.

[20]郑磊, 路佳. 单细胞测序技术及其在结直肠癌中的应用[J]. Tianjin Medical Journal, 2021, 49(8).